Bioprocessing News and Research

RSS

Embryonic stem cell therapy for incurable Stargardt eye disease

...

26 Sep 2011

USDA NIFA awards NC State $25M grant to study human noroviruses

North Carolina State University will use a $25 million grant from the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) to strengthen food safety by studying human noroviruses across the food supply chain in an effort to design effective control measures and reduce the number of virus-caused food-borne illnesses.

4 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

Sanofi Pasteur establishes new vaccine research and development facility in Canada

Mark Lievonen, President of Sanofi Pasteur Limited, and Premier Dalton McGuinty today opened a $101 million dollar vaccine research and development facility at Sanofi Pasteur's Connaught Campus in north Toronto. This new facility establishes the Connaught Campus as the North American Centre of Excellence in analytical and bioprocessing R&D for Sanofi Pasteur globally.

23 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Scientists discover four different bacteria that can live on caffeine

As it turns out, humans aren't the only organisms that turn to caffeine for a pick-me-up. University of Iowa scientists have identified four different bacteria that actually can live on caffeine.

8 Jun 2011

Almac launches six enzyme screening kits

As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.

4 May 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

TAP announces new corporate identity

The Automation Partnership, a leading supplier of innovative automation for life science applications today announced that the company will now be known as TAP Biosystems.

30 Mar 2011

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life science process applications, has announced the official launch of two new core modules for off-line data processing in its fourth generation TruBio DV software. These modules are targeted at enabling bioprocessing specialists to manage data from third party equipment and process analyzers, and obtain automated electronic records of their batch.

21 Mar 2011

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis Technologies Inc. is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

28 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.

2 Nov 2010

iBio and CMB enter development and marketing collaboration with GE Healthcare

iBio, Inc., its development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company, today announced their entry into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies.

2 Sep 2010

CMC Biologics completes new, disposable manufacturing facility at Seattle

CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site. The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.

25 Aug 2010

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

The University of Louisville has received a $3.15 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to support the UofL James Graham Brown Cancer Center and cancer research taking place in Owensboro. The grant will be matched with state "Bucks for Brains" funding to bring more than $4.5 million to the Owensboro Cancer Research Program.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, an Eppendorf Company, and Pall Corporation today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

From Pall Corporation 14 Jun 2010